For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $7.13 in the prior trading day, Tscan Therapeutics Inc (NASDAQ: TCRX) closed at $6.75, down -5.33%. In other words, the price has decreased by -$5.33 from its previous closing price. On the day, 1.64 million shares were traded. TCRX stock price reached its highest trading level at $7.35 during the session, while it also had its lowest trading level at $6.58.
Ratios:
Our goal is to gain a better understanding of TCRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.51 and its Current Ratio is at 6.51. In the meantime, Its Debt-to-Equity ratio is 0.61 whereas as Long-Term Debt/Eq ratio is at 0.57.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wedbush on June 22, 2023, initiated with a Outperform rating and assigned the stock a target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 19 ’23 when BARBERICH TIMOTHY J bought 317 shares for $4.97 per share. The transaction valued at 1,575 led to the insider holds 67,027 shares of the business.
BARBERICH TIMOTHY J bought 28,830 shares of TCRX for $140,881 on Dec 18 ’23. The Director now owns 66,710 shares after completing the transaction at $4.89 per share. On Dec 14 ’23, another insider, Klencke Barbara, who serves as the Director of the company, bought 5,000 shares for $5.08 each. As a result, the insider paid 25,400 and bolstered with 30,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCRX now has a Market Capitalization of 323356736 and an Enterprise Value of 223593824. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.99 while its Price-to-Book (P/B) ratio in mrq is 2.14. Its current Enterprise Value per Revenue stands at 10.623 whereas that against EBITDA is -2.538.
Stock Price History:
The Beta on a monthly basis for TCRX is 0.94, which has changed by 1.5 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, TCRX has reached a high of $9.00, while it has fallen to a 52-week low of $1.62. The 50-Day Moving Average of the stock is -2.68%, while the 200-Day Moving Average is calculated to be 48.26%.
Shares Statistics:
The stock has traded on average 163.50K shares per day over the past 3-months and 272380 shares per day over the last 10 days, according to various share statistics. A total of 47.83M shares are outstanding, with a floating share count of 36.46M. Insiders hold about 16.42% of the company’s shares, while institutions hold 67.85% stake in the company. Shares short for TCRX as of 1711584000 were 219413 with a Short Ratio of 1.34, compared to 1709164800 on 187726. Therefore, it implies a Short% of Shares Outstanding of 219413 and a Short% of Float of 0.5700000000000001.
Earnings Estimates
The company has 4 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.25 for the current quarter, with a high estimate of -$0.24 and a low estimate of -$0.27, while EPS last year was -$0.93. The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.24 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$1 and -$1.11 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$1.11, with 4 analysts recommending between -$0.95 and -$1.18.
Revenue Estimates
4 analysts predict $3.97M in revenue for the current quarter. It ranges from a high estimate of $5.4M to a low estimate of $2.5M. As of the current estimate, Tscan Therapeutics Inc’s year-ago sales were $6.8M, an estimated decrease of -41.60% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $4.07M, an increase of 29.30% over than the figure of -$41.60% in the same quarter last year. There is a high estimate of $5.51M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 4 analysts have provided revenue estimates for TCRX’s current fiscal year. The highest revenue estimate was $22.5M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $16.51M. In the same quarter a year ago, actual revenue was $21.05M, down -21.60% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $11.37M in the next fiscal year. The high estimate is $21.98M and the low estimate is –$. The average revenue growth estimate for next year is down -31.10% from the average revenue estimate for this year.
